Skip To Main Content

Glofitamab (CD20 x CD3)

(RG6026)

HEMATOLOGY

Phase III

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (STARGLO)

NCT04408638

Phase II

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283

Phase I

A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03075696

A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL

NCT03467373

An Open-Label Phase lB Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723

This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

CD20- and CD3-targeting bispecific antibody for B-cell malignancies

Glofitamab (also known as RO7082859, RG6026) is an investigational, full-length, CD20- and CD3-targeting T-cell bispecific antibody that is designed to redirect T cells to engage and eliminate malignant B cells.1-4 Glofitamab is designed to bind to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies, while simultaneously binding to CD3, a component of the TCR on the surface of T cells.1,2,5,6 Glofitamab is equipped with an Fc region that has been engineered to abolish FcγRs and C1q binding while maintaining FcRn binding, which may allow for an extended circulatory half-life.1,2,7 In preclinical models, glofitamab demonstrated anticancer activity, including T-cell activation, proliferation, and B-cell killing.1,2 Furthermore, glofitamab administered with a PD-L1– blocking antibody led to enhanced inhibition of tumor growth in preclinical combination studies.2

1. Optimized structure facilitates activity against cancer cells

Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker. This unique structure allows for high-avidity binding to CD20 that can result in activity against B cells even under low effector-to-target (E:T) cell ratios.1,2

Optimized structure against cancer cells

2. Developed to direct immune cells to attack and kill cancer cells

Upon binding to CD20 on a B cell and CD3 on a T cell, glofitamab may induce activation of the T cell and subsequent formation of an immunologic synapse between the two cells.1,2,6 This is followed by secretion of cytotoxic granules, including perforin and granzyme, by the activated T cell. Perforin creates large transmembrane pores on the surface of the bound B cell, allowing granzymes to enter the cell. Granzymes trigger a series of biochemical reactions, resulting in B-cell lysis.8,9

Direct immune cells designed to attack cancer cells

3. Anticancer effects demonstrated in preclinical studies

In preclinical models of multiple B-cell malignancies, glofitamab administration led to B-cell killing and tumor regression. Preclinical models also suggest glofitamab activity leads to the proliferation/expansion of T cells at the site of activation and increased intra-tumor T-cell infiltration.1,2 Glofitamab continues to be investigated in ongoing clinical trials, including in combination with PD-L1 inhibition, for B-cell malignancies.10

Death of cancer cell

C1q=complement component 1, q subcomponent; CD=cluster of differentiation; Fab=fragment antigen binding; Fc=fragment crystallizable; FcγR=Fc gamma receptor; FcRn=neonatal Fc receptor; PD-L1=programmed death-ligand 1; TCR=T-cell receptor.
 

Watch how Glofitamab redirects T cells and how it engages B cells.

Glofitamab proposed MOA

Watch how glofitamab redirects T cells and how it engages B cells.

    • Bacac M, Colombetti S, Herter S, et al. Clin Cancer Res. 2018. doi:10.1158/1078-0432.CCR-18-0455. PMID: 29716920

      Bacac M, Colombetti S, Herter S, et al. Clin Cancer Res. 2018. doi:10.1158/1078-0432.CCR-18-0455. PMID: 29716920

    • Bacac M, Umaña P, Herter S, et al. Blood. 2016;128:1836.

      Bacac M, Umaña P, Herter S, et al. Blood. 2016;128:1836.

    • Joosten V, Lokman C, van den Hondel CA, Punt PJ. Microb Cell Fact. 2003;2:1. PMID: 12605725

      Joosten V, Lokman C, van den Hondel CA, Punt PJ. Microb Cell Fact. 2003;2:1. PMID: 12605725

    • Johnson M. Labome validated antibody database. https://www.labome.com/method/Antibody-Structure-and-Fragments.html. Updated July 29, 2018. Accessed August 23, 2018.

      Johnson M. Labome validated antibody database. https://www.labome.com/method/Antibody-Structure-and-Fragments.html. Updated July 29, 2018. Accessed August 23, 2018.

    • Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448

      Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. Diagn Pathol. 2011;6:33. PMID: 21486448

    • Frankel SR, Baeuerle PA. Curr Opin Chem Biol. 2013;17:385-392. PMID: 23623807

      Frankel SR, Baeuerle PA. Curr Opin Chem Biol. 2013;17:385-392. PMID: 23623807

    • Wang X, Mathieu M, Brezski RJ. Protein Cell. 2018;9:63-73. PMID: 28986820

      Wang X, Mathieu M, Brezski RJ. Protein Cell. 2018;9:63-73. PMID: 28986820

    • Dieckmann NMG, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. J Cell Sci. 2016;129:2881-2886. PMID: 27505426

      Dieckmann NMG, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. J Cell Sci. 2016;129:2881-2886. PMID: 27505426

    • Thiery J, Keefe D, Boulant S, et al. Nat Immunol. 2011;12:770-777. PMID: 21685908

      Thiery J, Keefe D, Boulant S, et al. Nat Immunol. 2011;12:770-777. PMID: 21685908

    • Roche. HY 2021 results. July 22, 2021. https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf. Accessed July 26, 2021.

      Roche. HY 2021 results. July 22, 2021. https://www.roche.com/dam/jcr:a1437516-3f73-4112-a483-40c8b1c3836e/en/irp210722.pdf. Accessed July 26, 2021.